Previous Close | 13.17 |
Open | 13.23 |
Bid | 12.83 x 900 |
Ask | 13.25 x 800 |
Day's Range | 13.20 - 13.28 |
52 Week Range | 11.43 - 13.34 |
Volume | |
Avg. Volume | 147,287 |
Market Cap | 467.179M |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | 7.49 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.49 (11.21%) |
Ex-Dividend Date | May 14, 2024 |
1y Target Est | N/A |
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research. This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.